Journal
NEUROLOGY
Volume 59, Issue 5, Pages 744-746Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.59.5.744
Keywords
-
Categories
Ask authors/readers for more resources
Depression is a suspected side effect of treatment with interferon beta1a in MS. However, an association with depression has not been confirmed by rigorous studies. During the SPECTRIMS clinical trial of interferon beta1a (Rebif) in secondary progressive MS, depression ratings were obtained from 365 subjects treated either with interferon beta1a or with placebo. No significant differences between groups emerged during 36 months of follow-up. These data suggest that depression is not a side effect of interferon beta1a.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available